GET THE APP

Health improvement of HIV-1 infected patients treated by Immunorex TM: Lessons learned in 40 years on monoamine oxydase and DHEA metabolism research
..

Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Health improvement of HIV-1 infected patients treated by Immunorex TM: Lessons learned in 40 years on monoamine oxydase and DHEA metabolism research


4th World Congress on Cancer Science & Therapy

October 20-22, 2014 DoubleTree by Hilton Hotel Chicago-North Shore Conference Center, USA

Donatien Mavoungou

Accepted Abstracts: J Cancer Sci Ther

Abstract :

This lecture is to share our 40 years of experience on metabolism of monoamine oxydase and stress in rat model, followed by studies on DHEA and related peptides hormones ininflammatory conditionswhich leaded to ImmunorexTM. It can restore and prevent not only the TH1 TH2 deregulation focussing on IL 10 suppression known to enhance growth and dissemination of both HIV-1 and co-infected pathogens and to provoke cardiovascular and cerebrovascular diseases, but is also able to block overproduction of IL6 and IL10 suppressing B cells lymphomas. Consequently it restore, TH1 and NK cells to treat and prevent cell malignancies. ImmunorexTM demonstrated its capacity to block HIV-1 host cell entry through the restriction of the envelop proteins mediating cell-cell fusion (gp 120/gp 41) by inhibiting phosplolipase A2 (PLA2) activation suppressing new mutants resistance clinical isolate. Health improvement of HIV-1 infected patients was described by Maka et al, 2009; while in more recent datas, ImmunorexTM induced antibody dependent cellular cytotoxicity mediated by specific anti-VIH-1 IgG known to be implicated in vaccine induced immunity. The capacity of ImmunorexTM to control oxidative stress by inhibition of NADPH activation was also shown. ImmunorexTM showed its capacity to improve health in cases of prostatic and of laryngeal cancer and inone case of chronic myeloid leukemia attributable not only to DHEA but also to the presence of salicin and threonine in ImmunorexTM composition.

Biography :

Donatien Mavoungouis the Director of the Research Center on Hormonal Pathologies (CRPH) Gabon. He has authored more than 150 publications. He discovered IMMUNOREXTM DM28 inhibiting HIV-1 replication. He is Professor of Biochemistry and Endocrinology at the University of Health Science Libreville, Gabon. He received the Prize of the National Center for Scientific Research in 2009 and 2012. (Gabon).

Google Scholar citation report
Citations: 3968

Cancer Science & Therapy received 3968 citations as per Google Scholar report

Cancer Science & Therapy peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward